Tripoint Therapeutics

Tripoint Therapeutics is a biotechnology company focused on developing next-generation oncology treatments by targeting the complex interactions within the tumor microenvironment. The company's research centers on the tri-point relationship between malignant cells, the supporting stroma, and the immune system, particularly in recalcitrant cancers like pancreatic ductal adenocarcinoma. Founded by Dr. David Tuveson, a leader in pancreatic cancer research, Tripoint leverages deep biological insights to identify therapeutic vulnerabilities that traditional treatments fail to address. Their approach aims to dismantle the protective stromal barriers that shield tumors from the immune system and chemotherapy. Currently in the pre-clinical stage, the company is advancing a pipeline of small molecule candidates designed to reprogram the tumor microenvironment. Tripoint operates as a spin-out from Cold Spring Harbor Laboratory, utilizing advanced organoid models to validate its therapeutic targets.